SANDOZ GROUP AG

Explore Sandoz’s landmark collaboration with Shanghai Henlius Biotech, expanding its global biosimilar portfolio to 10 assets, boosting access and cost‑efficiency worldwide.

Unlocking a broader biosimilar portfolio, Sandoz partners with Shanghai Henlius Biotech to add up to ten new global assets—boosting revenue, expanding reach, and staying ahead in the fast‑growing biologics market.

How Sandoz’s U.S. generic strategy could reshape drug pricing, returns, and competition in a tariff‑heavy market.

Read how Sandoz’s new Rwanda deal will boost affordable cancer & antibiotic access in Sub‑Saharan Africa, cutting costs and strengthening supply chains.

Read how Sandoz Group AG’s March 2026 bond and credit deals cut debt costs, extend maturities, and fuel growth in generics and biosimilars.

FDA approves Sandoz’s Enzeevu for RVO, DR, and DME: clinical efficacy matches Eylea, offers cost‑effective, expanded retinal treatment.

European Commission approves Sandoz’s Ondibta, a biosimilar insulin, promising lower costs, wider access, and new competition in the EU insulin market.

Read how Sandoz’s acquisition of Just‑Evotec Biologics expands its biosimilar manufacturing power, cuts costs, and boosts market share in the $30 billion industry.

Read how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its continuous‑manufacturing biosimilar capacity, cutting costs and speeding market launch for affordable biologics.

Sandoz Group AG has announced several key developments, including the launch of a generic rivaroxaban treatment in Germany and a CAD 220 million investment in its Boucherville plant.